TROPION 03

A RANDOMIZED PHASE 3 STUDY OF DATOPOTOMAB DERUXTECAN PLUS CARBOPLATIN OR CISPLATIN VERSUS GEMCITABINE PLUS CARBOPLATIN OR CISPLATIN IN SUBJECTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA WHO HAVE PROGRESSED DURING OR AFTER ENFORTUMAB VEDOTIN PLUS PEMBROLIZUMAB COMBINATION TREATMENT